

## Cleansing Notice under section 708A(5)(e) of the Corporations Act

This notice is given by Microba Life Sciences Limited (ASX : MAP) (**Microba** or **Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

On 23 June 2025, Microba announced a capital raise to the ASX consisting of:

- a placement to raise \$12.5 million before costs by the issue of approximately 138,888,889 ordinary shares (**New Shares**) at \$0.09 per New Share, plus approximately 69,444,444 free-attaching options (**New Options**) on the basis of one (1) New Option for every two (2) New Shares subscribed for under the placement (**Placement**). The Placement will complete in two tranches, with 67,177,796 New Shares being issued under tranche 1 of the Placement (**Tranche 1 Placement Shares**); and
- a fully underwritten share purchase plan to eligible Microba shareholders to raise up to a further \$2.0 million before costs by the issue of approximately 22,222,223 New Shares at \$0.09 per New Share, plus approximately 11,111,111 free-attaching New Options on the basis of one (1) New Option for every two (2) New Shares subscribed for under the share purchase plan (**SPP Offer**).

The Tranche 1 Placement Shares were issued on 27 June 2025 and an Appendix 2A has been lodged with the ASX for quotation of those Tranche 1 Placement Shares.

### Details of the Placement

Details of the issue of Tranche 1 Placement Shares is provided below:

<b>Class of Securities:</b>	Tranche 1 Placement Shares are fully paid ordinary shares
<b>ASX Code of the securities:</b>	ASX: MAP
<b>Date of the issue:</b>	27 June 2025
<b>Total number of Tranche 1 Placement Shares:</b>	67,177,796

In accordance with section 708A(6) of the Corporations Act, Microba gives notice that:

- the Tranche 1 Placement Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- this notice is being given under section 708A(5)(e) of the Corporations Act;
- as of the date of this notice, the Company has complied with:
  - the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - sections 674 and 674A of the Corporations Act; and
- as of the date of this notice, there is no "excluded information" as defined in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by the Company.

*Authorised for release by the Board of Directors.*

For further information, please contact:

**Dr Luke Reid**

Chief Executive Officer

[luke.reid@microba.com](mailto:luke.reid@microba.com)

**Investor / Media Relations**

[investor@microba.com](mailto:investor@microba.com)

<https://ir.microba.com/welcome>



**JOIN MICROBA'S INTERACTIVE INVESTOR HUB**

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit [ir.microba.com/welcome](https://ir.microba.com/welcome)

**Microba Life Sciences Ltd** | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621